Table 1.

Patient and treatment characteristics

Deidentified number	Gender	Race	Ethnicity	Age at diagnosis	B-SX at DX	Initial stage	IPI	Bulky  > 10 cm	1st line of therapy	At least one relapse	2nd line of therapy	3rd line of therapy	4th line of therapy	FU in months	Status at last FU
PML01	Male	white	not Hispanic	46	No	II	1	Yes	6xDA-R-EPOCH	No				18	Alive
PML02	Female	Asian	not Hispanic	30	No	II	1	Yes	6xDA-R-EPOCH	No				32	Alive
PML03	Male	white	Hispanic	36	No	IV	2	No	6xDA-R-EPOCH	No				21	Alive
PML04	Male	white	not Hispanic	54	No	IV	2	Yes	6xDA-R-EPOCH	Yes	3xR-ICE, ASCT and XRT			65	Alive
PML05	Male	American Indian	not Hispanic	38	No	I	1	Yes	6xDA-R-EPOCH	No				26	Alive
PML06	Female	Hawaiian/Pacific Islander	Hispanic	29	Yes	II	1	Yes	6xDA-R-EPOCH	Yes	1 × R-DHAP	1xR-ICE, Liso-cel		29	Alive
PML07	Male	white	NA	30	Yes	III	1	Yes	1xABVD + 6xDA-R-EPOCH	Yes	3xR-DHAP, then ASCT	Selinexor and Rituximab	Rituximab + fractionated Cyclophosphamide	15	Dead
PML08	Female	white	not Hispanic	24	Yes	IV	2	No	6xDA-R-EPOCH	No				38	Alive
PML09	Female	white	not Hispanic	50	Yes	IV	3	Yes	6xDA-R-EPOCH	Yes	1xR-DHAP	Tisa-cel	7xPembrolizumab + XRT	31	Alive
PML10	Male	white	not Hispanic	22	No	II	0	No	4xDA-R-EPOCH	No				35	Alive
PML11	Male	white	not Hispanic	38	Yes	III	1	No	1xR-CHOP + Len,  + 5xDA-R-EPOCH	No				37	Alive
PML12	Female	white	not Hispanic	28	No	IV	1	No	5xDA-R-EPOCH	Yes	Axi-cel	8xPembrolizumab, ASCT and XRT		57	Alive

ABVD: doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine; ASCT: autologous stem cell transplantation; axi-cel: axicabtagene ciloleucel; DA-R-EPOCH: dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; DX: diagnosis; FU: follow-up; IPI: International Prognostic Index; Len: lenalidomide; Liso-cel: lisocabtagene maraleucel; NA: not available; R-DHAP: rituximab, cytosine arabinoside, dexamethasone; R-ICE: rituximab, ifosfamide, carboplatin, and etoposide; SX: symptoms;Tisa-cel: tisagenlecleucel; x: cycles; XRT: radiotherapy of the mediastinum